Essex LLC Cassava Sciences Inc Transaction History

Essex LLC

$482 Million
Q3 2024

A detailed history of Essex LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Essex LLC holds 69,774 shares of SAVA stock, worth $180,714. This represents 0.43% of its overall portfolio holdings.

Number of Shares

69,774

Previous 55,318 26.13%

Holding current value

$180,714

Previous $683,000 200.59%

% of portfolio

0.43%

Previous 0.16%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$9.57 - $35.08 $138,343 - $507,116	14,456 Added 26.13%	69,774 $2.05 Million
Q2 2024 Jul 22, 2024	BUY	$12.35 - $26.11 $57,353 - $121,254	4,644 Added 9.16%	55,318 $683,000
Q1 2024 May 03, 2024	BUY	$18.44 - $26.41 $293,196 - $419,919	15,900 Added 45.72%	50,674 $1.03 Million
Q4 2023 Jan 29, 2024	BUY	$12.64 - $30.11 $285,916 - $681,088	22,620 Added 186.11%	34,774 $782,000
Q3 2023 Oct 16, 2023	SELL	$16.64 - $25.32 $79,206 - $120,523	-4,760 Reduced 28.14%	12,154 $202,000
Q2 2023 Jul 31, 2023	BUY	$21.59 - $27.88 $36,983 - $47,758	1,713 Added 11.27%	16,914 $414,000
Q4 2022 Jan 30, 2023	SELL	$27.82 - $44.16 $207,759 - $329,786	-7,468 Reduced 32.94%	15,201 $449,000
Q3 2022 Nov 07, 2022	BUY	$16.33 - $51.06 $165,667 - $518,003	10,145 Added 81.0%	22,669 $948,000
Q2 2022 Aug 01, 2022	BUY	$17.22 - $38.47 $8,041 - $17,965	467 Added 3.87%	12,524 $352,000
Q1 2022 Apr 20, 2022	BUY	$32.6 - $53.05 $45,542 - $74,110	1,397 Added 13.11%	12,057 $448,000
Q4 2021 Jan 28, 2022	SELL	$36.77 - $90.91 $96,484 - $238,547	-2,624 Reduced 19.75%	10,660 $466,000
Q3 2021 Oct 21, 2021	BUY	$41.79 - $135.3 $555,138 - $1.8 Million	13,284 New	13,284 $825,000

Others Institutions Holding SAVA

# of Institutions

196

Shares Held

13.8M

Call Options Held

2.98M

Put Options Held

6.57M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $104M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Essex LLC, based on Form 13F filings with the SEC.

News

Stay updated on Essex LLC with notifications on news.

Account